Review Article| Volume 19, ISSUE 1, P125-135, January 2023

How to Treat Right Heart Failure. Tips for Clinicians in Everyday Practice


      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Heart Failure Clinics
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • McDonagh T.A.
        • Metra M.
        • Adamo M.
        • et al.
        2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: Developed by the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). With the special contribution of the Heart Failure Association (HFA) of the ESC.
        Eur J Heart Fail. 2022; 24: 4-131
        • Haddad F.
        • Doyle R.
        • Murphy D.J.
        • et al.
        Right ventricular function in cardiovascular disease, Part II - Pathophysiology, clinical importance, and management of right ventricular failure.
        Circulation. 2008; 117: 1717-1731
        • Konstam M.A.
        • Kiernan M.S.
        • Bernstein D.
        • et al.
        Evaluation and Management of Right-Sided Heart Failure: A Scientific Statement From the American Heart Association.
        Circulation. 2018; 137: e578-e622
        • Ghio S.
        • Guazzi M.
        • Scardovi A.B.
        • et al.
        Different correlates but similar prognostic implications for right ventricular dysfunction in heart failure patients with reduced or preserved ejection fraction.
        Eur J Heart Fail. 2017; 19: 873-879
        • Disalvo T.G.
        • Mathier M.
        • Semigran M.J.
        • et al.
        Preserved right-ventricular ejection fraction predicts exercise capacity and survival in advanced heart-failure.
        J Am Coll Cardiol. 1995; 25: 1143-1153
        • de Groote P.
        • Millaire A.
        • Foucher-Hossein C.
        • et al.
        Right ventricular ejection fraction is an independent predictor of survival in patients with moderate heart failure.
        J Am Coll Cardiol. 1998; 32: 948-954
        • Polak J.F.
        • Holman B.L.
        • Wynne J.
        • et al.
        Right ventricular ejection fraction: an indicator of increased mortality in patients with congestive heart failure associated with coronary artery disease.
        J Am Coll Cardiol. 1983; 2: 217-224
        • Salzano A.
        • D’Assante R.
        • Iacoviello M.
        • et al.
        Progressive right ventricular dysfunction and exercise impairment in patients with heart failure and diabetes mellitus: insights from the T.O.S.CA. Registry.
        Cardiovasc Diabetol. 2022; 21: 108
        • Ramani G.V.
        • Gurm G.
        • Dilsizian V.
        • et al.
        Noninvasive assessment of right ventricular function: will there be resurgence in radionuclide imaging techniques?.
        Curr Cardiol Rep. 2010; 12: 162-169
        • Obokata M.
        • Reddy Y.N.V.
        • Melenovsky V.
        • et al.
        Deterioration in right ventricular structure and function over time in patients with heart failure and preserved ejection fraction.
        Eur Heart J. 2019; 40: 689
        • Dellitalia L.J.
        Curr Probl Cardiol. 1991; 16: 659-720
        • Kawel-Boehm N.
        • Maceira A.
        • Valsangiacomo-Buechel E.R.
        • et al.
        Normal values for cardiovascular magnetic resonance in adults and children.
        J Cardiovasc Magn Reson. 2015; 17
        • Noordegraaf A.V.
        • Chin K.M.
        • Haddad F.
        • et al.
        Pathophysiology of the right ventricle and of the pulmonary circulation in pulmonary hypertension: an update.
        Eur Respir J. 2019; 53
        • Badagliacca R.
        • Reali M.
        • Poscia R.
        • et al.
        Right Intraventricular Dyssynchrony in Idiopathic, Heritable, and Anorexigen-Induced Pulmonary Arterial Hypertension Clinical Impact and Reversibility.
        Jacc-Cardiovascular Imaging. 2015; 8: 642-652
        • Galiè N.
        • Humbert M.
        • Vachiery J.L.
        • et al.
        2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT).
        Eur Heart J. 2016; 37: 67-119
        • Tang W.H.W.
        • Mullens W.
        Cardiorenal syndrome in decompensated heart failure.
        Heart. 2010; 96: 255-260
        • Johnson J.N.
        • Driscoll D.J.
        • O'Leary P.W.
        Protein-Losing Enteropathy and the Fontan Operation.
        Nutr Clin Pract. 2012; 27: 375-384
        • Mehra M.R.
        Fat, cachexia, and the right ventricle in heart failure: a web of complicity.
        J Am Coll Cardiol. 2013; 62 (20130731): 1671-1673
        • Marra A.M.
        • Sherman A.E.
        • Salzano A.
        • et al.
        Right Side of the Heart Pulmonary Circulation Unit Involvement in Left-Sided Heart Failure: Diagnostic, Prognostic, and Therapeutic Implications.
        Chest. 2021; : 20210927
        • Gorter T.M.
        • van Veldhuisen D.J.
        • Bauersachs J.
        • et al.
        Right heart dysfunction and failure in heart failure with preserved ejection fraction: mechanisms and management. Position statement on behalf of the Heart Failure Association of the European Society of Cardiology.
        Eur J Heart Fail. 2018; 20: 16-37
        • Lang R.M.
        • Badano L.P.
        • Mor-Avi V.
        • et al.
        Recommendations for Cardiac Chamber Quantification by Echocardiography in Adults: An Update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging.
        Eur Heart Journal-Cardiovascular Imaging. 2015; 16: 233-271
        • Anavekar N.S.
        • Skali H.
        • Bourgoun M.
        • et al.
        Usefulness of right ventricular fractional area change to predict death, heart failure, and stroke following myocardial infarction (from the VALIANT ECHO study).
        Am J Cardiol. 2008; 101: 607-612
        • Mohammed S.F.
        • Hussain I.
        • Abou Ezzeddine O.F.
        • et al.
        Right Ventricular Function in Heart Failure With Preserved Ejection Fraction A Community-Based Study.
        Circulation. 2014; 130 (2310-U2186)
        • Contaldi C.
        • Dellegrottaglie S.
        • Mauro C.
        • et al.
        Role of Cardiac Magnetic Resonance Imaging in Heart Failure.
        Heart Failure Clin. 2021; 17 (20210203): 207-221
        • Salzano A.
        • D'Assante R.
        • Israr M.Z.
        • et al.
        Biomarkers in Heart Failure: Clinical Insights.
        Heart Failure Clin. 2021; 17 (20210210): 223-243
        • Suzuki T.
        • Lyon A.
        • Saggar R.
        • et al.
        Editor's Choice-Biomarkers of acute cardiovascular and pulmonary diseases.
        Eur Heart Journal-Acute Cardiovasc Care. 2016; 5: 416-433
        • Salzano A.
        • Marra A.M.
        • D'Assante R.
        • et al.
        Biomarkers and Imaging: Complementary or Subtractive?.
        Heart Fail Clin. 2019; 15: 321-331
        • Padang R.
        • Chandrashekar N.
        • Indrabhinduwat M.
        • et al.
        Aetiology and outcomes of severe right ventricular dysfunction.
        Eur Heart J. 2020; 41: 1273
        • Ponikowski P.
        • Voors A.A.
        • Anker S.D.
        • et al.
        2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC.
        Eur J Heart Fail. 2016; 18: 891-975
        • Harjola V.P.
        • Mebazaa A.
        • Čelutkienė J.
        • et al.
        Contemporary management of acute right ventricular failure: a statement from the Heart Failure Association and the Working Group on Pulmonary Circulation and Right Ventricular Function of the European Society of Cardiology.
        Eur J Heart Fail. 2016; 18: 226-241
        • Simon M.A.
        Assessment and treatment of right ventricular failure.
        Nat Rev Cardiol. 2013; 10: 204-218
        • Maddox T.M.
        • Januzzi J.L.
        • Allen L.A.
        • et al.
        2021 Update to the 2017 ACC Expert Consensus Decision Pathway for Optimization of Heart Failure Treatment: Answers to 10 Pivotal Issues About Heart Failure With Reduced Ejection Fraction: A Report of the American College of Cardiology Solution Set Oversight Committee.
        J Am Coll Cardiol. 2021; 77 (20210111): 772-810
        • Heidenreich P.A.
        • Bozkurt B.
        • Aguilar D.
        • et al.
        2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: Executive Summary: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines.
        J Am Coll Cardiol. 2022; 79 (20220401): 1757-1780
        • Bursi F.
        • Barbieri A.
        • Grigioni F.
        • et al.
        Prognostic implications of functional mitral regurgitation according to the severity of the underlying chronic heart failure: a long-term outcome study.
        Eur J Heart Fail. 2010; 12: 382-388
        • Stone G.W.
        • Lindenfeld J.
        • Abraham W.T.
        • et al.
        Transcatheter Mitral-Valve Repair in Patients with Heart Failure.
        N Engl J Med. 2018; 379: 2307-2318
        • Obadia J.F.
        • Messika-Zeitoun D.
        • Leurent G.
        • et al.
        Percutaneous Repair or Medical Treatment for Secondary Mitral Regurgitation.
        N Engl J Med. 2018; 379: 2297-2306
        • Bertaina M.
        • Galluzzo A.
        • D'Ascenzo F.
        • et al.
        Prognostic impact of MitraClip in patients with left ventricular dysfunction and functional mitral valve regurgitation: A comprehensive meta-analysis of RCTs and adjusted observational studies.
        Int J Cardiol. 2019; 290: 70-76
        • Nishimura R.A.
        • Bonow R.O.
        Percutaneous Repair of Secondary Mitral Regurgitation - A Tale of Two Trials.
        N Engl J Med. 2018; 379: 2374-2376
        • Seferovic P.M.
        • Ponikowski P.
        • Anker S.D.
        • et al.
        Clinical practice update on heart failure 2019: pharmacotherapy, procedures, devices and patient management. An expert consensus meeting report of the Heart Failure Association of the European Society of Cardiology.
        Eur J Heart Fail. 2019; 21: 1169-1186
        • Abraham W.T.
        • Adamson P.B.
        • Bourge R.C.
        • et al.
        Wireless pulmonary artery haemodynamic monitoring in chronic heart failure: a randomised controlled trial.
        Lancet. 2011; 377: 658-666
        • Hoendermis E.S.
        • Liu L.C.
        • Hummel Y.M.
        • et al.
        Effects of sildenafil on invasive haemodynamics and exercise capacity in heart failure patients with preserved ejection fraction and pulmonary hypertension: a randomized controlled trial.
        Eur Heart J. 2015; 36: 2565-2573
        • Bonderman D.
        • Ghio S.
        • Felix S.B.
        • et al.
        Riociguat for patients with pulmonary hypertension caused by systolic left ventricular dysfunction: a phase IIb double-blind, randomized, placebo-controlled, dose-ranging hemodynamic study.
        Circulation. 2013; 128: 502-511
        • Vachiéry J.L.
        • Delcroix M.
        • Al-Hiti H.
        • et al.
        Macitentan in pulmonary hypertension due to left ventricular dysfunction.
        Eur Respir J. 2018; 51
        • Bermejo J.
        • Yotti R.
        • García-Orta R.
        • et al.
        Sildenafil for improving outcomes in patients with corrected valvular heart disease and persistent pulmonary hypertension: a multicenter, double-blind, randomized clinical trial.
        Eur Heart J. 2018; 39: 1255-1264
        • Guazzi M.
        • Vicenzi M.
        • Arena R.
        • et al.
        PDE5 inhibition with sildenafil improves left ventricular diastolic function, cardiac geometry, and clinical status in patients with stable systolic heart failure: results of a 1-year, prospective, randomized, placebo-controlled study.
        Circ Heart Fail. 2011; 4: 8-17
        • Vachiéry J.L.
        • Tedford R.J.
        • Rosenkranz S.
        • et al.
        Pulmonary hypertension due to left heart disease.
        Eur Respir J. 2019; 53
        • Marra A.M.
        • Egenlauf B.
        • Ehlken N.
        • et al.
        Change of right heart size and function by long-term therapy with riociguat in patients with pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension.
        Int J Cardiol. 2015; 195: 19-26
        • Frey M.K.
        • Lang I.
        Tadalafil for the treatment of pulmonary arterial hypertension.
        Expert Opin Pharmacother. 2012; 13 (20120223.): 747-755
        • Galie N.
        • Barbera J.A.
        • Frost A.E.
        • et al.
        Initial Use of Ambrisentan plus Tadalafil in Pulmonary Arterial Hypertension.
        N Engl J Med. 2015; 373: 834-844
        • Prasad S.
        • Wilkinson J.
        • Gatzoulis M.A.
        Sildenafil in primary pulmonary hypertension.
        N Engl J Med. 2000; 343: 1342
        • Samarzija M.
        • Zuljevic E.
        • Jakopovic M.
        • et al.
        One Year Efficacy and Safety of Oral Sildenafil Treatment in Severe Pulmonary Hypertension.
        Coll Antropol. 2009; 33: 799-803
        • Galie N.
        • Ghofrani H.A.
        • Torbicki A.
        • et al.
        Sildenafil citrate therapy for pulmonary arterial hypertension.
        N Engl J Med. 2005; 353: 2148-2157
        • Sastry B.K.S.
        • Narasimhan C.
        • Reddy N.K.
        • et al.
        Clinical efficacy of sildenafil in primary pulmonary hypertension - A randomized, placebo-controlled, double-blind, crossover study.
        J Am Coll Cardiol. 2004; 43: 1149-1153
        • De Santo L.S.
        • Buonocore M.
        • Agrusta F.
        • et al.
        Pattern of resolution of pulmonary hypertension, long-term allograft right ventricular function, and exercise capacity in high-risk heart transplant recipients listed under oral sildenafil.
        Clin Transplant. 2014; 28: 837-843
        • Galie N.
        • Brundage B.H.
        • Ghofrani H.A.
        • et al.
        Tadalafil Therapy for Pulmonary Arterial Hypertension.
        Circulation. 2009; 119 (2894-U2865)
        • Simonneau G.
        • Rubin L.J.
        • Galie N.
        • et al.
        Addition of Sildenafil to Long-Term Intravenous Epoprostenol Therapy in Patients with Pulmonary Arterial Hypertension A Randomized Trial.
        Ann Intern Med. 2008; 149 (521-W102)
        • Marra A.M.
        • Bossone E.
        • Salzano A.
        • et al.
        Biomarkers in Pulmonary Hypertension.
        Heart Fail Clin. 2018; 14: 393
        • Marra A.M.
        • Egenlauf B.
        • Bossone E.
        • et al.
        Principles of rehabilitation and reactivation: pulmonary hypertension.
        Respiration. 2015; 89: 265-273
        • Grünig E.
        • Eichstaedt C.
        • Barberà J.A.
        • et al.
        ERS statement on exercise training and rehabilitation in patients with severe chronic pulmonary hypertension.
        Eur Respir J. 2019; 53: 2019-20102/28
        • Kitzman D.W.
        • Brubaker P.
        • Morgan T.
        • et al.
        Effect of Caloric Restriction or Aerobic Exercise Training on Peak Oxygen Consumption and Quality of Life in Obese Older Patients With Heart Failure With Preserved Ejection Fraction: A Randomized Clinical Trial.
        JAMA. 2016; 315: 36-46
        • Salzano A.
        • De Luca M.
        • Israr M.Z.
        • et al.
        Exercise Intolerance in Heart Failure with Preserved Ejection Fraction.
        Heart Fail Clin. 2021; 17: 397-413
        • Crisci G.
        • De Luca M.
        • D’Assante R.
        • et al.
        Effects of exercise on heart failure with preserved ejection fraction. An updated review of literature.
        J Cardiovasc Development Dis. 2022; 9: 241
        • Lampert B.C.
        • Teuteberg J.J.
        Right ventricular failure after left ventricular assist devices.
        J Heart Lung Transplant. 2015; 34: 1123-1130
        • Soliman O.I.I.
        • Akin S.
        • Muslem R.
        • et al.
        Derivation and Validation of a Novel Right-Sided Heart Failure Model After Implantation of Continuous Flow Left Ventricular Assist Devices: The EUROMACS (European Registry for Patients with Mechanical Circulatory Support) Right-Sided Heart Failure Risk Score.
        Circulation. 2018; 137: 891-906
        • Bellavia D.
        • Iacovoni A.
        • Scardulla C.
        • et al.
        Prediction of right ventricular failure after ventricular assist device implant: systematic review and meta-analysis of observational studies.
        Eur J Heart Fail. 2017; 19: 926-946
        • Verbelen T.
        • Verhoeven J.
        • Goda M.
        • et al.
        Mechanical support of the pressure overloaded right ventricle: an acute feasibility study comparing low and high flow support.
        Am J Physiology-Heart Circulatory Physiol. 2015; 309: H615-H624